Short Report

Perinatal outcomes associated with the use of glargine during pregnancy

G. Di Cianni, E. Torlone*, C. Lencioni, M. Bonomo**, A. Di Benedetto†, A. Napoli‡, E. Vitacolonna§, D. Mannino§§, A. Lapolla¶ for the Italian Diabetes and Pregnancy Study Group, Italian Society of Diabetology

Department of Endocrinology and Metabolism, Section of Diabetes and Metabolic Diseases, University of Pisa, Pisa, Italy, *Department of Internal Medicine Endocrinology and Metabolism, University of Perugia, Perugia, **Interdisciplinary Diabetes and Pregnancy Center, Niguarda Ca’ Granda Hospital, Milano, †Department of Internal Medicine, University of Messina, Messina, §Department of Clinical Sciences University La Sapienza Rome, Roma, §§Diabetes Unit, University of Chieti, Chieti, ¶Department of Endocrinology and Diabetology, Hospital Bianchi, Malacrinco, Morelli - Reggio Calabria, ‡Department of Clinical and Surgical Sciences, University of Padova, Padova

Accepted 20 February 2008

Abstract

Aims Insulin glargine (IG), with its non-peaking action profile, might be useful in diabetic pregnancy. However, data on its safety are limited and its use during pregnancy is not recommended. This study focused on the effects of IG on perinatal outcome, particularly to estimate the rate of congenital anomalies and birthweight.

Methods This retrospective study included women with pre-gestational diabetes who used IG before (at least 1 month) and during pregnancy. For all women we recorded data regarding maternal glycaemic control and pregnancy outcome. We also compared women treated with IG throughout pregnancy and women who stopped taking IG at an earlier stage.

Results From 27 centres, 107 Type 1 diabetic pregnancies were identified. IG was started 10.3 ± 6.9 months before conception and in 57.4% of cases was stopped during the first trimester; 42.6% of women continued using it until the end of pregnancy. There were six abortions (four spontaneous and two induced) and five newborns (4.9%) with congenital anomalies. Glycaemic control, birthweight and the prevalence of macrosomia and neonatal morbidity were similar in women who used IG for the full term compared with those who stopped IG earlier during pregnancy.

Conclusions This study, although limited, suggests that IG is safe and effective; the rate of congenital malformations was within the range expected for diabetic pregnancies treated with more traditional forms of insulin. IG used throughout pregnancy did not seem to influence birthweight or increase adverse outcomes.

Diabet. Med. 25, 993–996 (2008)

Keywords birthweight, congenital malformations, diabetes, insulin glargine, pregnancy

Abbreviations HbA1c, glycated haemoglobin; IFG-1, insulin-like growth factor 1; IG, insulin glargine; LGA, large for gestational age; NICU, neonatal intensive care unit; NPH, neutral protamine Hagedorn; PI, ponderal index

Introduction

Insulin glargine (IG), with its characteristic non-peaking action profile [1], could be useful in diabetic pregnancies, where strict glycaemic control and prevention of hypoglycaemia are essential to reduce adverse outcomes [2,3]. However, in view of the lack of controlled data on its safety, the use of IG is currently not recommended in pregnant women. Another...
Potential concern is that the higher affinity of insulin glargine for the insulin-like growth factor 1 (IGF-1) receptor compared with other insulin preparations [4] might cause increased fetal growth, in spite of good glycaemic control. As a consequence, although IG is frequently prescribed for young patients with diabetes, its use during pregnancy is still limited and diabetologists have often discontinued IG during the periconceptional period or at first consultation during unplanned pregnancies.

To date, studies on IG in pregnancy have involved only a small number of women with pre-gestational diabetes [5–13] and more systematic studies are lacking. The Italian Diabetes Pregnancy Study Group has therefore promoted a national survey to collect data on the use of IG in women with pre-gestational diabetes. This study focuses on the effects of IG on the perinatal outcome, particularly examining the rate of congenital anomalies and birthweight.

Methods

This retrospective study included 107 women from 27 Italian centres with pre-gestational diabetes who used IG before (at least 1 month) and during pregnancy. Centres were contacted by scientific diabetology or obstetric societies, during their national and regional meetings and via their websites. Investigators were asked to record data of all pregnancies in women with IG-treated pre-gestational diabetes that had ended before 31 December 2006. We collected data from women who had been treated with IG during their entire pregnancy and women who had stopped taking IG earlier in pregnancy. The study was approved by local ethics committees and women gave their informed consent to the collection of information from their medical records.

Basal clinical data were gathered from the first visit after conception: glycated haemoglobin (HbA\(_1c\)), bodyweight and insulin therapy were recorded. HbA\(_1c\) values at the end of the pregnancy (1–2 weeks before delivery), frequency of episodes of severe hypoglycaemia and ketosis were used to assess overall glycaemic control during pregnancy. Severe hypoglycaemia was assumed in the event of hypoglycaemic emergencies where the woman required assistance. Ketosis was considered an episode of severe hyperglycaemia with an abnormally high concentration of ketone bodies in urine.

Regarding maternal outcome, gestational hypertension, pre-eclampsia, eclampsia, time and mode of delivery and maternal mortality were recorded. Information about abortions was obtained from hospital records. For neonatal outcome, data were collected for length and weight at birth, congenital malformations, shoulder dystocia, hypoglycaemia, fetal distress, jaundice, stillbirth and early neonatal mortality. Macrosomia was assumed in the event of hypoglycaemic emergencies where the other and had had diabetes for longer (Table 1).

Delivery occurred in 101 pregnancies at 36.7 ± 2.1 weeks of gestation. The rates of pre-term deliveries and Caesarean section were 29.7 and 79.2% respectively. No maternal death was reported. All babies were living at birth; one baby, born preterm at the 29th week of gestation with a weight of 1215 g, died a few days after delivery; 23.3% of newborns were admitted to a NICU.

The rates of LGA and excessive growth (PI > 2.85 g/cm\(^3\)) did not differ significantly between women who used IG throughout the pregnancy and those who stopped it earlier (Table 1). The rates of macrosomia were also similar in the two groups (20.9 and 14.8%, respectively). Five newborns had congenital malformations (4.95%), two cardiovascular, two genitourinary and one osteoarticular. Mothers of malformed infants were significantly older (P < 0.001) than the others and had had diabetes for longer (P < 0.04).

Discussion

This survey collected data on 107 pregnancies of women with Type 1 diabetes. This is one of the most extensive surveys reported on this topic in recent years [5–13]. Almost all the pregnancies were unplanned; in view of the lack of controlled data on the safety and efficacy of IG, when pregnancy is planned diabetologists usually change the drug. For the same reason, as
a policy of the diabetes centres, in our series IG was stopped at confirmation of pregnancy in a large number of women.

We therefore identified two groups of pregnant women (Table 1) who were clinically comparable; this was useful as a basis for assessing the effects of IG on maternal glycaemic control and on birthweight.

To determine the safety of IG in pregnancy, the study first focused on congenital malformation, given that IG was used during embryogenesis in all women. The rate of congenital anomalies was 4.95%. This figure is within the range (from 3.2 to 9%) expected for diabetic pregnancies treated with other forms of insulin, as recently reported in several European countries [18–23]. Moreover, in a previous multicentre survey of 504 Italian women with pre-gestational Type 1 diabetes (none taking IG either before or during pregnancy), we found a similar rate of congenital malformations of 5.9% [24]. It is worth noting that 19 out of 27 centres were involved in both surveys and that the two cohorts of pregnant diabetic women had similar clinical and metabolic characteristics. Thus, the present results suggest that IG has no negative effects on embryo-fetal development.

Another issue is the potential effect on fetal growth. One concern is that the higher affinity of IG for IGF-1 receptor compared with other insulin preparations [4] could potentially cause fetal macrosomia. However, in our series, the use of IG throughout pregnancy was not associated with higher birthweight or any change in neonatal outcome. In addition, the prevalence of macrosomia and/or LGA infants was no different from women who used NPH insulin in pregnancy. This result might possibly be because of comparable metabolic parameters (HbA1c at the end of pregnancy, episodes of hypoglycaemia and ketosis) in the two groups, factors which are the main determinants of birthweight in diabetic pregnancies [25]. Thus, as recently reported in other studies [11,12], the absence of higher rates of macrosomic and LGA babies in women treated with IG does seem to exclude any increase in the risk of fetal overgrowth as a result of this type of therapy.

Although we are aware of the limited size of our cohort and the need for larger randomized trials in order to strengthen the findings, this survey, which at present is one of the largest reporting pregnancy outcomes in women treated with IG, does seem to exclude any increase in the risk of fetal overgrowth as a result of this type of therapy.

In conclusion, IG in pregnancy seems to give much the same maternal-neonatal outcomes as older insulins.

### Participating investigators

The members of the Italian Diabetes and Pregnancy Study Group—Italian Society of Diabetology include: Graziano Di

### Table 1: Maternal and fetal outcome according to type of insulin treatment

|                          | Group A (n = 43) | Group B (n = 58) | P     |
|--------------------------|-----------------|-----------------|-------|
| **Mothers**              |                 |                 |       |
| Age (years)              | 30.6 ± 3.5      | 30.4 ± 4.1      | 0.79  |
| Diabetes duration (years)| 16.8 ± 8.7      | 15.9 ± 6.5      | 0.55  |
| Pre-pregnancy BMI (kg/m²)| 23.2 ± 4.9      | 24.2 ± 3.4      | 0.325 |
| Weight gain (kg)         | 14.1 ± 4.1      | 13.3 ± 4.4      | 0.55  |
| HbA1c (%)                |                 |                 |       |
| —first measurement in pregnancy | 7.7 ± 1.32     | 7.6 ± 1.09      | 0.688 |
| —at the end of pregnancy | 6.5 ± 0.79      | 6.5 ± 0.91      | 0.97  |
| Patients with hypoglycaemic episodes (%) | 9.3            | 12.1            | 1.00  |
| Patients with episodes of ketosis (%) | 11.6           | 6.9             | 0.56  |
| Gestational hypertension (%) | 2.3            | 3.4             | 0.32  |
| Pre-eclampsia (%)        | 2.3             | 8.6             | 0.8   |
| Time of delivery (weeks) | 37.2 ± 1.5      | 36.4 ± 2.4      | 0.045 |
| Caesarean section (%)    | 79.1            | 79.3            | 0.89  |
| **Newborns**             |                 |                 |       |
| Large for gestational age (%) | 44.1          | 41.3            | 0.85  |
| Ponderal index (kg/cm³)  | 2.8 ± 0.4       | 2.8 ± 0.3       | 0.92  |
| Ponderal index > 2.85 (%)| 45.0            | 46.9            | 1     |
| Congenital malformations (%) | 4.7            | 5.2             | 1     |
| NICU admissions (%)      | 25.7            | 21.5            | 0.4   |
| Neonatal hypoglycaemia (%)| 14.6           | 17.2            | 0.72  |
| Hyperbilirubinaemia (%)  | 19.5            | 22.2            | 0.62  |

Group A: patients with insulin glargine throughout pregnancy. Group B: patients who stopped insulin glargine in pregnancy and started using intermediate human insulin. BMI, body mass index; HbA1c, glycated haemoglobin; NICU, neonatal intensive care unit.
Cianni (Pisa), Elisabetta Torlone (Perugia) Cristina Lencioni (Pisa), Alessandra Battezzati (Alessandria), Matteo Bonomo (Milano), Daniela Bruuttomesso (Padova), Gelsomina Capuano (Salerno), Silvana Caronna (Parma), Adolfo Ciavarella (Bologna), Maria Grazia Dall'ra (Padova), Eugenio De Feo (Napoli), Antonio Di Benedetto (Messina), Maria Dolci (Massa), Ivano Franzetti (Varese), Raffaella Fresa (Cava dei Tirreni-Salerno), Paola Gelisio (Mestre-Venezia), Alessandra Ghio (Pisa), Maria Pia Imbergamo (Palermo), Giovanna Losato (Rovigo), Valeria Manicardi (Reggio Emilia), Domenico Mannino (Reggio Calabria), Guido Menato (Torino), Marina Miola (Schio-Vicenza), Elena Mion (Milano), Mary Mori (Massa), Angela Napoli (Roma), Alessandro Pianta (Bassano Del Grappa-Treviso), Costanza Santini (Cesena), Laura Sciocca (Catania), Giancarlo Tomolo (Sassari), Laura Tonutti (Udine), Carla Tortol (Monfalcone-Gorizia), Ester Vitacolonna (Chieti), Laura Volpe (Pisa) and Annunziata Lapolla (Padova).

Competing interest
Nothing to declare.

Acknowledgement
This study was supported by a grant from the Italian Society of Diabetology (SID).

References
1 Owens DR, Zinman B, Boli GB. Insulin today and beyond. Lancet 2001; 358: 739–746.
2 Temple R, Aldige Y, Greenwood R, Heypam R, Sampson M, Stanley K. Association between outcome of pregnancy and glycaemic control in early pregnancy in Type 1 diabetes: a population-based study. Br Med J 2002; 325: 1275–1276.
3 Manderson JG, Patterson CC, Hadden DR, Traub Al, Ennis C, McCance DR. Preprandial versus postprandial blood glucose monitoring in Type 1 diabetic pregnancy: a randomized controlled clinical trial. Am J Obstet Gynecol 2003; 189: 507–512.
4 Slieker LJ, Brooke GS, Di Marchi R, Flora D, Green LK, Hoffmann JA. Modifications in the B10 and B26–30 regions of the B chain of human insulin alter affinity for the human IGF-1 receptor more than for the insulin receptor. Diabetologia 1997; 40: 54–61.
5 Devlin JT, Hetherhill L, Wilkes JL. Use of insulin glargine during pregnancy in a Type 1 diabetic woman. Diabet Care 2002; 25: 1093–1096.
6 Holeson A, Plaschke A, Egberts EH. Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes. Diabet Med 2003; 20: 779–780.
7 Di Cianni G, Volpe L, Lencioni C, Chiazzinagnostos K, Cacciu I, Ghio A et al. Use of insulin glargine during the first week of pregnancy in five Type 1 diabetic women. Diabetes Care 2003; 26: 982–983.
8 Dolci M, Moro M, Baccetti F. Use of glargine before and during pregnancy in a woman with Type 1 diabetes and Addison’s disease. Diabetes Care 2005; 28: 2084–2085.
9 Wooldrake JM, van Loon AJ, Storms F, de Heide L, Hoogendijk K. Use of insulin glargine during pregnancy in seven Type 1 diabetic women. Diabetes Care 2005; 28: 2594–2595.
10 Torlone E, Gennarini A, Ricci NB, Boli GB. Successful use of insulin glargine during entire pregnancy until delivery in six Type 1 diabetic women. Eur J Obstet Gynecol 2007; 132: 236–239.
11 Price N, Bartlett C, Gilmer MD. Use of insulin glargine during pregnancy: a case-control pilot study. Br J Obstet Gynaecol 2007; 11: 453–457.
12 Feyhonen-Alho M, Tapani R, Saltevo J, Ekblad U, Kaaja RJ. Use of insulin glargine during pregnancy. Acta Obstet Gynecol Scand 2007; 86: 1171–1174.
13 Gallen PW, Jaap A, Roland JM, Chayrath HH. Survey of glargine use in 115 pregnant women with Type 1 diabetes. Diabet Med 2008; 25: 165–169.
14 Parazzini F, Cortinovis I, Bortullos R, Fedele L, Recarli A. Weight at birth by gestational age in Italy. Hum Reprod 1995; 10: 1852–1863.
15 Langer O, Yogey Y, Most O, Xenakis EMJ. Gestational diabetes: the consequences of not treating. Am J Obstet Gynecol 2005; 192: 989–997.
16 Lechat MF, Dohi H. Registries of congenital anomalies: EUROCAT. Environ Health Perspect 1993; 101: 153–157.
17 Johansen KS, Hold M. Quality development in perinatal care—the OBSQID project. Int J Gynaecol Obstet 1999; 64: 167–172.
18 Casson IF, Clarke CA, Howard CV, McKendrik O, Pennycook S, Pharao PO et al. Outcome of pregnancy in insulin-dependent diabetic women: result of a five-year population cohort study. Br Med J 1997; 314: 275–278.
19 Penney GC, Mair G, Pearson DW. Outcomes of pregnancies in women with Type 1 diabetes in Scotland: a national population-based study. Br J Obstet Gynaecol 2003; 110: 315–318.
20 Diabetes and Pregnancy Group France. French multicenter survey of outcome of pregnancy in women with pre-gestational diabetes. Diabetes Care 2005; 28: 2990–2993.
21 Evers IM, de Valk FW, Visser GHA. Risk of complications of preg- nancy in women with Type 1 diabetes: nationwide prospective study in the Netherlands. Br J Obstet Gynaecol 2004; 111: 913–917.
22 Jensen DM, Damun P, Mohtar-Pedersen L, Ovesen P, Westergaard JD, Moeller M et al. Outcomes in Type 1 diabetic pregnancies. A nationwide population-based study. Diabetes Care 2004; 27: 2819–2823.
23 Macintosh MCM, Fleming KM, Bailey JA, Doyle P, Modler J, Acolet D et al. Perinatal mortality and congenital anomalies in babies of women with Type 1 or Type 2 diabetes in England, Wales and Northern Ireland: a population-based study. Br Med J 2006; 333: 177–180.
24 Lapolla A, Dall’ra MG, Di Cianni G, Bonomo M, Parretti E, Mello G for the Scientific Committee of the GISOD Group. A multicenter Italian study on pregnancy outcome in women with diabetes. Nutr Metab Cardiovasc Dis 2008; 18: 283–297.
25 Langer O. Fetal macrosomia: etiologic factors. Clin Obstet Gynecol 2000; 43: 283–297.